Cross-reactive protection against influenza a virus by a topically applied DNA vaccine encoding M gene with adjuvant

Viral Immunology

Volumn 18, Issue 2, 2005, Pages 373-380

  Ozaki, Tomomi ^a   Yauchi, Masaomi ^a   Xin, Ke Qin ^a   Hirahara, Fumiki ^a   Okuda, Kenji ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; DNA VACCINE; EXOTOXIN; IMMUNOLOGICAL ADJUVANT; M PROTEIN; OLIGONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CPG ISLAND; CROSS REACTION; CYTOTOXICITY; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOCOMPETENT CELL; INFLUENZA VIRUS A; MOUSE; NONHUMAN; VACCINATION; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS; INFLUENZA VACCINES; INTERFERON TYPE II; MALE; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION; VACCINES, DNA; VIRAL MATRIX PROTEINS;

INFLUENZA A VIRUS; INFLUENZAVIRUS A;

EID: 23344439552     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2005.18.373     Document Type: Article

References (36)

1. Aman, A.T., et al. 2001. A mutant cholera toxin B subunit that binds GM1-ganglioside but lacks immunomodulatory or toxic activity. Proc. Natl. Acad. Sci. U.S.A. 98:8536-8541.
2. Beignon, A.-S., et al. 2002. Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells. Immunology 105:204-212.
3. Beignon, A.S., et al. 2002. The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4+ T cells and secrete gamma interferon after coapplication onto bare skin. Infect. Immun. 70:3012-3019.
4. Chen D., et al. 2001. Adjuvantation of epidermal powder immunization. Vaccine 19:2908-2917.
5. Chen D., et al. 2001. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J. Virol. 75:7956-7965.
6. Davis H.L., I. Suparto, R. Weeratna. 2000. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18:1920-1924.
7. Donnelly, J., A. Friedman, D. Martinez. 1995. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med. 1:583-587.
8. Epstein, S.L., et al. 2002. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg. Infect. Dis. 8:796-801.
9. Fan H., et al. 1999. Immunization via hair follicles by topical application of naked DNA to normal skin. Nat. Biotech. 17:870-872.
10. Glenn, G.M., et al. 1998. Skin immunization made possible by cholera toxin. Nature 391:851.
11. Glenn G.M., et al. 1998. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161:3211-3214.
12. Glenn, G.M., et al. 2000. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6:1403-1406.
13. Harymann, G., A.M. Krieg. 2000. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164:944-952.
14. Hemmi, H., et al. 2000. A toll-like receptor recognizes bacterial DNA. Nature 408:740-745.
15. Hiromoto, Y., et al. 2000. Evolutionary characterization of the six internal genes of H5N1 human influenza A virus. J. Gen. Virol. 81:1293-1303.
16. Hunolstein, C.V., S. Mariotti, R. Teloni. 2001. The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophillus influenzae type B glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines. Vaccine 19:3058-3066.
17. Jackson, M.M., P. Lynch. 1989. Infection prevention and control in the era of the AIDS/HIV epidemic. Semin. Oncol. Nurs. 5:236-243.
18. Kawamura, Y.I., et al. 2003. Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NF-κB translocation. Eur. J. Immunol. 33:3205-3212.
19. Kojima, Y., et al. 2002. Adjuvant effect of multi-CpG motifs on an HIV-1DNA vaccine. Vaccine 20:2857-2865.
20. Mayfield, E. 1993. Protecting patients and professional from blood-borne disease. FDA Consumer 27:9-13.
21. Miyahara, Y., K. Murata, D. Rodriguez. 1995. Quantification of antigen-specific CD8+ T cells using an ELISpot assay. J. Immunol. Methods 181:45-54.
22. Neirynck, S., et al. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5:1157-1163.
23. Nguyen, H.H., et al. 2000. Gamma interferon is not required for mucosal cytotoxic T-lymphocyte responses or heterosubtypic immunity to influenza A virus infection in mice. J. Virol. 74:5495-5501.
24. Okada, E., et al. 1997. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte macrophage colony stimulating factor (GM-CSF) expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J. Immunol. 159:3638-3647.
25. Okuda, K., et al. 2001. Protective immunity against influenza A virus induced with DNA plasmid containing influenza M gene. Vaccine 19:3681-3691.
26. Scharton-Kersten, T., et al. 2000. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits and unrelated adjuvants. Infect. Immun. 68:5306-6313.
27. Schulman, J.L., E.D. Kilbourne. 1965. Induction of partial specific heterotypic immunity in mice by a single infection with influenza virus. J. Bacteriol. 89:170-174.
28. Shi Z., et al. 2001. Protection against tetanus by needle free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J. Virol. 75:11474-11482.
29. Spangler, B.D. 1992. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:622-647.
30. Takeshita, F. 2001. Role of toll like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 167: 3555-3558.
31. Ulmer, J., R. Deck, C. DeWitt. 1994. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine 12:1541-1544.
32. Verthelyi, D., R.A. Zeuner. 2003. Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends Immunol. 24:519-522.
33. Watabe, S., et al. 2001. Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 19:4434-4444.
34. Wolf, A.A., Y. Fujinaga, W.I. Lencer. 2002. Uncoupling of the cholera toxin-GM1 ganglioside receptor complex from endocytosis, retrograde Golgi trafficking, and downstream signal transduction by depletion of membrane cholesterol. J. Biol. Chem. 277:16249-16256.
35. Yewdell, J.W., et al. 1985. Influenza virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 82:1785-1789.
36. Yu J., et al. 2002. Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect. Immun. 70:1056-1068.